Measles-Rubella Elimination Campaign 

Context: The Ministry of Health and Family Welfare has launched the National Zero Measles-Rubella Elimination campaign 2025-26, marking a significant step towards India’s goal of eliminating Measles and Rubella by 2026.

🦠 About Measles

1. Causative Agent

  • Caused by the measles virus.

  • Type: Single-stranded, negative-sense, enveloped RNA virus.

2. Transmission

  • Highly contagious.

  • Spreads via:

    • Airborne droplets from coughs and sneezes.

    • Direct contact with nasal or mouth secretions.

3. Symptoms

  • Initial: High fever, cough, runny nose, red watery eyes.

  • Later:

    • Red rash starting from hairline and cheeks, spreading to trunk and limbs.

    • Koplik spots: Small white spots inside the mouth.

  • Complications: Ear infections, diarrhea, pneumonia, and in severe cases, death.

    • Fatality Rate: 5–10%.

4. Measles Vaccine

  • First developed in 1963.

  • Has prevented over 9 crore (90 million) deaths globally.

  • Reduces risk of measles infection by 20-fold.

  • Lifelong immunity usually after infection or vaccination.

  • Not zoonotic: Does not occur in animals.


🌸 About Rubella (German Measles)

1. Causative Agent

  • Caused by the rubella virus.

  • Targets: Lymph nodes, skin, eyes.

2. Transmission

  • Spread via droplets from coughs/sneezes.

  • Also through direct contact with oral or nasal fluids.

3. Symptoms

  • Milder than measles:

    • Low-grade fever

    • Rash

    • Sore throat

  • Usually not severe in adults but dangerous for pregnant women:

    • Risk of Congenital Rubella Syndrome (CRS) affecting fetal development.


🎯 Measles-Rubella Elimination Campaign (2025–26)

1. Objective

  • Eliminate Measles and Rubella, similar to Polio and Maternal-Neonatal Tetanus elimination.

  • ‘ACT NOW’ policy to ensure rapid and complete coverage.

2. Vaccination Strategy

  • Two doses under Universal Immunisation Programme (UIP):

    • First dose: 9–12 months

    • Second dose: 16–24 months

  • Provided free of cost to all eligible children.

3. Current Coverage (2024–25 HMIS Data)

  • 1st dose coverage: 93.7%

  • 2nd dose coverage: 92.2%

4. Progress

  • In 2024, compared to 2023:

    • Measles cases down by 73%

    • Rubella cases down by 17%

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top